Zusammenfassung
Prospektive Untersuchungen zur Gabe von Antikoagulanzien und Antiarrhythmika nach Vorhofflimmerablation liegen bislang nicht vor. Allerdings existieren Expertenempfehlungen aus dem Jahre 2007, die zu Indikation und Dauer einer Antikoagulation sowie zum Einsatz von Antiarrhythmika nach der Ablationsprozedur Stellung nehmen. Eine orale Antikoagulation wird für alle Patienten postinterventionell für mindestens 2 Monate empfohlen. Bei Patienten mit einem CHADS2-Score ≥2 sollte die Antikoagulation generell nicht beendet werden, unabhängig vom Vorhandensein oder Typ des Vorhofflimmerns. Antiarrhythmika können in den ersten 3 Monaten nach Ablation Vorhofflimmerrezidive unterdrücken, die in erster Linie auf postablatorischen inflammatorischen Prozessen beruhen. Auch nach Absetzen der Antiarrhythmika auftretende Arrhythmierezidive lassen sich medikamentös antiarrhythmisch behandeln, da primär wirkungslose Antiarrhythmika nach dem Ablationsversuch durchaus effektiv sein können.
Abstract
There are still no prospective studies concerning the use of anticoagulants and antiarrhythmic drugs after catheter ablation of atrial fibrillation. However, since 2007 experts have been stating recommendations for the indication and duration of anticoagulation as well as for the use of antiarrhythmic drugs after the ablation procedure. Postinterventionally oral anticoagulation is recommended for all patients for at least 2 months. Anticoagulation should continue in all patients who have a CHADS2 score ≥2, the type or persistence of atrial fibrillation then is not important. For the first 3 months antiarrhythmic drugs can successfully suppress relapses of atrial fibrillation which are caused by post-interventional tissue inflammation. In case of a relapse of atrial fibrillation antiarrhythmic drugs, which were initially ineffective, could be used successfully after the catheter ablation.
Literatur
Bertaglia E, Stabile G, Senatore G, Zoppo F, Turco P, Amellone C, De SA, Fazzari M, Pascotto P (2005) Predictive value of early atrial tachyarrhythmias recurrence after circumferential anatomical pulmonary vein ablation. Pacing Clin Electrophysiol 28:366–371
Calkins H, Brugada J, Packer DL, Cappato R, Chen SA, Crijns HJG, Damiano RJ, Davies DW, Haines DE, Haissaguerre M, Iesaka Y, Jackman W, Jais P, Kottkamp H, Kuck KH, Lindsay BD, Marchlinski FE, McCarthy PM, Mont JL, Morady F, Nademanee K, Natale A, Pappone C, Prystowsky E, Raviele A, Ruskin JN, Shemin RJ (2007) HRA/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. Heart Rhythm 4:816–861
Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, Kim YH, Klein G, Packer D, Skanes A (2005) Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 111:1100–1105
Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S (2006) ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary. Eur Heart J 27:1979–2030
Gage BF, Waterman AD, Shannon W et al (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285:2864–2870
Haissaguerre M, Jais P, Shah DC, Garrigue S, Takahashi A, Lavergne T, Hocini M, Peng JT, Roudaut R, Clementy J (2000) Electrophysiological end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary venous foci. Circulation 101:1409–1417
Hindricks G, Piorkowski C, Tanner H, Kobza R, Gerds-Li JH, Carbucicchio C, Kottkamp H (2005) Perception of atrial fibrillation before and after radiofrequency catheter ablation: relevance of asymptomatic arrhythmia recurrence. Circulation 112:307–313
Hocini M, Sanders P, Jais P, Hsu LF, Takahashi Y, Rotter M, Clementy J, Haissaguerre M (2004) Techniques for curative treatment of atrial fibrillation. J Cardiovasc Electrophysiol 15:1467–1471
Karch MR, Zrenner B, Deisenhofer I, Schreieck J, Ndrepepa G, Dong J, Lamprecht K, Barthel P, Luciani E, Schömig A, Schmitt C (2005) Freedom from atrial tachyarrhythmias after catheter ablation of atrial fibrillation: A randomized comparison between 2 current ablation strategies. Circulation 111:2875–2880
Kirchhof P, Breithardt G (2007) Therapie von Vorhofflimmern. Internist 48:819–831
Kuck KH, Ernst S, Dorwarth U, Hoffmann E, Pitschner H, Tebbenjohanns J, Kottkamp H (2007) Leitlinien zur Katheterablation. Clin Res Cardiol 96:833–849
Lee SH, Tai CT, Hsieh MH, Tsai CF, Lin YK, Tsao HM, Yu WC, Huang JL, Ueng KC, Cheng JJ et al (2004) Predictors of early and late recurrence of atrial fibrillation after catheter ablation of paroxysmal atrial fibrillation. J Interv Card Electrophysiol 10:221–226
Lemola K, Desjardins B, Sneider M, Case I, Cugh A, Good E, Han J, Tamirisa K, Tsemo A, Reich S, Tschopp D, Igic P, Elmouchi D, Bogun F, Pelosi F, Kazerooni E, Morady F, Oral H (2005) Effect of left atrial circumferential ablation for atrial fibrillation on left atrial transport function. Heart Rhythm 2:923–928
Mewis C, Neuberger HR, Böhm M (2006) Vorhofflimmern. Dtsch Med Wochenschr 131:2843–2854
Nademanee K, McKenzie J, Kosar E, Schwab M, Sunsaneewitayakul B, Vasavakul T, Khunnawat C, Ngarmukos T (2004) A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate. J Am Coll Cardiol 43:2044–2053
Oral H, Chugh A, Özaydin M, Good E, Fortino J, Sankaran S, Reich S, Igic P, Elmouchi D, Tschopp D, Wimmer A, Dey S, Crawford T, Pelosi F, Jongnarangsin K, Bogun F, Morady F (2006) Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation. Circulation 114:759–765
Oral H, Knight BP, Özaydin M, Tada H, Chugh A, Hassan S, Scharf C, Lai SW, Greenstein R, Pelosi F et al (2002) Clinical significance of early recurrences of atrial fibrillation after pulmonary vein isolation. J Am Coll Cardiol 40:100–104
Ouyang F, Antz M, Ernst S, Hachiya H, Mavrakis H, Deger FT, Schaumann A, Chun J, Falk P, Hennig D et al (2005) Recovered pulmonary vein conduction as a dominant factor for recurrent atrial tachyarrhythmias after complete circular isolation of the pulmonary veins: lessons from double Lasso technique. Circulation 111:127–135
Pappone C, Santinelli V (2004) The who, what, why, and how-to guide for circumferential pulmonary vein ablation. J Cardiovasc Electrophysiol 15:1226–1230
Schauerte P, Scherlag BJ, Pitha J, Scherlag MA, Reynolds D, Lazzara R, Jackman WM (2000) Catheter ablation of cardiac autonomic nerves for prevention of vagal atrial fibrillation. Circulation 102:2774–2780
Senatore G, Stabile G, Bertaglia E, Donnici G, De Simone A, Zoppo F, Turco P, Pascotto P, Fazzari M (2005) Role of transtelephonic electrocardiographic monitoring in detecting short-term arrhythmia recurrences after radiofrequency ablation in patients with atrial fibrillation. J Am Coll Cardiol 45:873–876
van Walraven WC, Hart RG, Wells GA et al (2003) A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med 163:936–943
Verma A, Marrouche NF, Natale A (2004) Pulmonary vein antrum isolation: Intracardiac echocardiographyguided technique. J Cardiovasc Electrophysiol 15:1335–1340
Wyse DG (2007) Anticoagulation in atrial fibrillation: A contemporary viewpoint. Heart Rhythm 4:S35–S39
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Volkmann, H., Bergmann, C. & Walter, M. Antikoagulation und Antiarrhythmika nach Vorhofflimmerablation. Clin Res Cardiol Suppl 3, 118–123 (2008). https://doi.org/10.1007/s11789-008-0035-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11789-008-0035-y